Drug Patent Watch
MARCH 5, 2025
The Future of Diabetes Care: How Biosimilar Insulin Products Are Revolutionizing Treatment As we continue to navigate the ever-evolving landscape of diabetes care, one thing is clear: innovation is key. And when it comes to insulin therapy, a game-changing trend is emerging: biosimilar insulin products.
Express Pharma
JUNE 26, 2025
Biocon Biologics (BBL), a biosimilars company and subsidiary of Biocon, has announced that Health Canada has granted a Notice of Compliance (NOC) for YESAFILI (aflibercept), a biosimilar to EYLEA (aflibercept) injection. YESAFILI is the first biosimilar to EYLEA to be approved by Health Canada.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 13, 2025
Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%
Big Molecule Watch
JULY 3, 2025
In its June 2025 meeting, the European Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) adopted positive opinions for six biosimilar medicines. Stay tuned to Big Molecule Watch as we continue to cover developments in the biosimilars industry.
PharmaVoice
JUNE 23, 2025
In general, the megablockbuster trend is skewing toward drugs that reach a wider range of patients, such as checkpoint inhibitors like Keytruda and GLP-1 weight loss and diabetes medications. Combined, Lilly’s Mounjaro, for diabetes, and Zepbound, for obesity, raked in $16.5 billion last year.
Express Pharma
MARCH 16, 2025
To move from generics to novel drug development, Indian companies must invest heavily in R&D for innovative therapies like biosimilars, cell and gene therapies, and specialty drugs. Similarly, Dr. Reddy’s and Cipla are exploring the biosimilar and complex generics space, focusing on areas like respiratory and oncology drugs.
Express Pharma
JUNE 29, 2025
Biocon Biologics (BBL), a global biosimilars company, announced that its Malaysian subsidiary, Biocon Sdn. This milestone marks a key development in BBL’s support for diabetes care and insulin accessibility in Malaysia. Every cartridge we produce at our state-of-the-art facility in Johor is a lifeline for someone living with diabetes.
Expert insights. Personalized for you.
52 
Let's personalize your content